Halozyme: 'Accidental' Business Model Has Exciting Upside Opportunities In 2025
Halozyme provides subcutaneous drug delivery solutions, with several major new products recently approved. Click here to find ...
Halozyme to Host Investor Conference Call to Provide Updated 2025 Financial Guidance
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will host an Investor Conference Call on Wednesday ...
Hosted on MSN12h
The Zacks Rank Explained: How to Find Strong Buy Medical Stocks
Building a successful investment portfolio takes skill and hard work, no matter if you're a growth, value, income, or momentum-focused investor. But what's the best way to find the right combination ...
The American Journal of Managed Care5d
FDA Approves First Subcutaneous Nivolumab Injection in Most Solid Tumors
FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.
Halozyme Announces argenx's VYDURA with ENHANZE® was Granted Regulatory Approval in Japan for Chronic Inflammatory Demyelinating Polyneuropathy
Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx's VYVDURA (efgartigimod alfa and ...
Business Insider8d
Halozyme Says FDA Approved Bristol Myers's Opdivo Qvantig With ENHANZE For Subcutaneous Use
(RTTNews) - Halozyme Therapeutics, Inc. (HALO) Monday said that the Food and Drug Administration (FDA) has approved Bristol Myers Squibb's Opdivo Qvantig co-formulated with Halozyme's ENHANZE drug ...
Halozyme announces Vyvdura co-formulated with Enhanze granted MHLW approval
Halozyme announced that Argenx’s Vyvdura, which is co-formulated with Halozyme’s Enhanze drug delivery technology, was granted regulatory approval by Japan’s Ministry of Hea ...
Nasdaq8d
Halozyme reports FDA approval for Opdivo co-formulated with Enhanze
Halozyme (HALO) announced that Bristol Myers Squibb (BMY) received FDA approval for Opdivo Qvantig co-formulated with Halozyme’s Enhanze drug delivery technology for subcutaneous use in most ...
Nasdaq8d
Halozyme announces Vyvdura co-formulated with Enhanze granted MHLW approval
Halozyme (HALO) announced that Argenx’s (ARGX) Vyvdura, which is co-formulated with Halozyme’s Enhanze drug delivery technology, was granted regulatory approval by Japan’s Ministry of Health ...
Morningstar9d
Halozyme Announces argenx's VYDURA with ENHANZE® was Granted Regulatory Approval in Japan for Chronic Inflammatory Demyelinating Polyneuropathy
"We are pleased that VYVDURA, with our innovative ENHANZE drug delivery technology, is now approved for two indications in Japan, enabling greater flexibility and optionality for generalized ...
Medindia8d
Halozyme Announces argenx's VYDURA with ENHANZE® was Granted Regulatory Approval in Japan for Chronic Inflammatory Demyelinating Polyneuropathy
SAN DIEGO, Dec. 30, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx's VYVDURA (efgartigimod alfa and hyaluronidase-qvfc), which is co ...